OSA and Tirzepatide

Obstructive sleep apnea drives a vicious metabolic cycle where intermittent nocturnal hypoxia and sleep fragmentation exacerbate systemic inflammation, oxidative stress, and insulin resistance. Weight loss remains the cornerstone of disease modification, but lifestyle interventions frequently fail long-term. Tirzepatide, a dual GIP/GLP-1 receptor agonist, addresses this by achieving profound, sustained total body weight reduction. In clinical trials, tirzepatide significantly reduces the apnea-hypopnea index alongside improvements in sleep-disordered breathing metrics, blood pressure, and metabolic markers. Dual receptor agonism targets the underlying upper airway mechanical collapse by reducing parapharyngeal adipose tissue while simultaneously improving systemic cardiometabolic risk profiles in patients with moderate-to-severe OSA.